Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter R Carroll

Showing results (121-130 of 589) with videos related to

Pageof 59
Sort By:
Cancer|July 29, 2009
Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURERobert Abouassaly, Alan Paciorek, Charles J Ryan, et al.
Australasian Journal on Ageing|September 7, 2012
Characteristics of older and younger patients with suspected paracetamol toxicityAlice Kane, Sarah J Mitchell, Peter R Carroll, et al.
Current Opinion in Urology|August 23, 2019
Active surveillance for intermediate-risk prostate cancer: yes, but for whom?Maya R Overland, Samuel L Washington, Peter R Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Urologist density and county-level urologic cancer mortalityAnobel Y Odisho, Matthew R Cooperberg, Vincent Fradet, et al.
Cancer|December 1, 2007
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomesPiyush K Agarwal, Natalia Sadetsky, Badrinath R Konety, et al.
Urologic Oncology|May 3, 2008
Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE databaseO Kenneth Macdonald, Anthony V D'Amico, Natalia Sadetsky, et al.
Cancer|February 23, 2007
Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortalityAnthony V D'Amico, David G McLeod, Peter R Carroll, et al.
The Journal of Urology|June 15, 2007
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data BaseKevin A David, Matthew I Milowsky, Jamie Ritchey, et al.
The Journal of Urology|December 19, 2008
Geographic distribution of urologists throughout the United States using a county level approachAnobel Y Odisho, Vincent Fradet, Matthew R Cooperberg, et al.
Urologic Oncology|April 14, 2009
The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancerMichael L Eisenberg, Janet E Cowan, Benjamin J Davies, et al.
Pageof 59

Showing results (121-130 of 589) with videos related to

Sort By:
Pageof 59
Cancer|July 29, 2009
Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURERobert Abouassaly, Alan Paciorek, Charles J Ryan, et al.
Australasian Journal on Ageing|September 7, 2012
Characteristics of older and younger patients with suspected paracetamol toxicityAlice Kane, Sarah J Mitchell, Peter R Carroll, et al.
Current Opinion in Urology|August 23, 2019
Active surveillance for intermediate-risk prostate cancer: yes, but for whom?Maya R Overland, Samuel L Washington, Peter R Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Urologist density and county-level urologic cancer mortalityAnobel Y Odisho, Matthew R Cooperberg, Vincent Fradet, et al.
Cancer|December 1, 2007
Treatment failure after primary and salvage therapy for prostate cancer: likelihood, patterns of care, and outcomesPiyush K Agarwal, Natalia Sadetsky, Badrinath R Konety, et al.
Urologic Oncology|May 3, 2008
Predicting PSA failure following salvage radiotherapy for a rising PSA post-prostatectomy: from the CaPSURE databaseO Kenneth Macdonald, Anthony V D'Amico, Natalia Sadetsky, et al.
Cancer|February 23, 2007
Time to an undetectable prostate-specific antigen (PSA) after androgen suppression therapy for postoperative or postradiation PSA recurrence and prostate cancer-specific mortalityAnthony V D'Amico, David G McLeod, Peter R Carroll, et al.
The Journal of Urology|June 15, 2007
Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data BaseKevin A David, Matthew I Milowsky, Jamie Ritchey, et al.
The Journal of Urology|December 19, 2008
Geographic distribution of urologists throughout the United States using a county level approachAnobel Y Odisho, Vincent Fradet, Matthew R Cooperberg, et al.
Urologic Oncology|April 14, 2009
The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancerMichael L Eisenberg, Janet E Cowan, Benjamin J Davies, et al.
Pageof 59